The Expression Levels and Clinical Significance of CARDS TX, MyD88, and IL‐8 of Children With Severe Mycoplasma pneumoniae Pneumonia
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1)
Abstract
Objective: To investigate the expression levels of community‐acquired respiratory distress syndrome toxin (CARDS TX), myeloid differentiation factor 88 (MyD88), and interleukin‐8 (IL‐8) in the bronchoalveolar lavage fluid (BALF) of children with severe Mycoplasma pneumoniae pneumonia (SMPP) and explore their clinical significance in the pathogenesis of SMPP. Methods: This was a retrospective analysis of clinical data from 29 patients with SMPP and 12 patients with general Mycoplasma pneumoniae pneumonia (GMPP). Moreover, the expression levels of CARDS TX, MyD88, and IL‐8 in the BALF of the two groups were detected and compared. Results: The expression levels of CARDS TX, MyD88, and IL‐8 were positively correlated with SMPP ( p < 0.05). Univariate logistic regression analysis indicated that CARDS TX, MyD88, and IL‐8 are potential risk factors for SMPP ( p < 0.05). The areas under the curve for the CARDS TX, MyD88, and IL‐8 assays were 0.857, 0.730, and 0.799, respectively. The optimal cutoff values were 10.91 ng/mL, 2.21 ng/mL, and 120.52 pg/mL, respectively. Conclusions: Elevated levels of CARDS TX, MyD88, and IL‐8 in BALF all demonstrate diagnostic utility for children with SMPP, with CARDS TX exhibiting the highest diagnostic sensitivity. A CARDS TX concentration >10.91 ng/mL, a MyD88 concentration >2.21 ng/mL, and an IL‐8 concentration >120.52 pg/mL are potential risk factors for SMPP.Keywords
Funding Information
- Henan Provincial Science and Technology Research Project (252102311119)
This publication has 27 references indexed in Scilit:
- A comparison of diagnostic and therapeutic approaches for Mycoplasma pneumoniae pneumonia in children and adults, during the post-COVID-19 pandemic eraEuropean Journal of Clinical Microbiology & Infectious Diseases, 2025
- Reemergence of Mycoplasma pneumoniae disease: Pathogenesis and new approachesMicrobial Pathogenesis, 2024
- Exploring the pathogenicity of Mycoplasma pneumoniae: Focus on community-acquired respiratory distress syndrome toxinsMicrobial Pathogenesis, 2024
- The correlation between the level of cellular classification in bronchoalveolar lavage fluid of children with severe Mycoplasma pneumoniae and clinical characteristicsEuropean Journal of Pediatrics, 2024
- Oxidative stress in the alveolar lavage fluid of children with Mycoplasma pneumoniae pneumoniaPediatric Pulmonology, 2024
- Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumoniaEuropean Journal of Pediatrics, 2024
- Clinical features of severe Mycoplasma pneumoniae pneumonia with pulmonary complications in childhood: A retrospective studyPediatric Pulmonology, 2023
- Vaccine using community-acquired respiratory distress syndrome toxin as an antigen against Mycoplasma pneumoniae in miceBiochemical and Biophysical Research Communications, 2022
- Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010–2019Journal of the Formosan Medical Association, 2021
- Development of 2-amino-4-phenylthiazole analogues to disrupt myeloid differentiation factor 88 and prevent inflammatory responses in acute lung injuryEuropean Journal of Medicinal Chemistry, 2019